SAS2 C1	
    			    			
                CCMi008-A            
            
        General
Cell Line | 
					|
| hPSCreg name | CCMi008-A | 
| Cite as: | CCMi008-A (RRID:CVCL_C3QV) | 
| Alternative name(s) | 
									 
	SAS2 C1	 
							 | 
						
| Cell line type | Human induced pluripotent stem cell (hiPSC) | 
| Similar lines | 
							 | 
					
| Last update | 4th January 2023 | 
| User feedback | |
Provider | 
					|
| Generator | Centro Cardiologico Monzino IRCCS (CCM) | 
External Databases | 
						|
| Cellosaurus | CVCL_C3QV | 
| BioSamples | SAMEA112286913 | 
| Wikidata | Q116048700 | 
							    
							General Information | 
					|
| Publications | |
| * Is the cell line readily obtainable for third parties? | 
                                     Yes                                                                                 Research use: allowed 
                                                                                    Clinical use: allowed 
                                                                                    Commercial use: not allowed 
                                                                         | 
                            
Donor Information
General Donor Information | 
					|
| Sex | male | 
| Ethnicity | Caucasian | 
Phenotype and Disease related information (Donor) | 
					|
| Diseases | A disease was diagnosed.
																	 | 
					
Karyotyping (Donor) | 
						|
| Has the donor karyotype been analysed? | 
								 Yes 								
																	
												46, XY
											 
																				
																													 | 
						
Other Genotyping (Donor) | 
						|
| Is there genome-wide genotyping or functional data available? | 
								 No 								
															 | 
						
External Databases (Donor) | 
						|
| BioSamples | SAMEA112286498 | 
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes | 
| Was the consent voluntarily given? | Yes | 
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes | 
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No | 
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes | 
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised | 
| Does consent explicitly allow the derivation of pluripotent stem cells? | No | 
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No | 
| How may genetic information associated with the cell line be accessed? | Controlled Access | 
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No | 
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes | 
| Name of accrediting authority involved? | Centro Cardiologico Monzino - IRCCS\IEO ethical committee | 
| Approval number | R1492/21-CCM1579 | 
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | 
hIPSC Derivation
General | 
						|
| Source cell type | 
										
				
	
			 A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes. 
	
			Synonyms 
		
  | 
							
Reprogramming method | 
						|
| Vector type | Non-integrating | 
| Vector | Episomal | 
| Is reprogramming vector detectable? | 
										 No 									 | 
								
| Methods used | 
										 
	PCR	 
									 | 
								
Vector free reprogramming | 
						|
Other | 
						|
| Derived under xeno-free conditions | 
								 Unknown 							 | 
						
| Derived under GMP? | 
								 Unknown 							 | 
						
| Available as clinical grade? | 
								 Unknown 							 | 
						
Culture Conditions
| Surface coating | Vitronectin | 
| Feeder cells | 
															 No 														 | 
						
| Passage method | 
								Enzyme-free cell dissociation
								
																											 
											ReLeSR										 
																	
							 | 
						
| O2 Concentration | 21 % | 
| CO2 Concentration | 5 % | 
| Medium | 
								Other medium:		 
			Base medium: StemFlex Medium			 
				
		
								Main protein source: Serum concentration: %  | 
						
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes  | 
					
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes  | 
					
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes  | 
					
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles | 
| SOX2 | 
											 Yes 						                 | 
																                
						                
							                 | 
						                ||||
| SSEA-4 | 
											 Yes 						                 | 
																                
						                
						                	 | 
						                ||||
| POU5F1 (OCT-4) | 
											 Yes 						                 | 
																                
						                
							                 | 
						                ||||
| LIN28 | 
											 Yes 						                 | 
																                
						                
							                 | 
						                
Differentiation Potency
In vitro directed differentiation
					In vitro directed differentiation
					In vitro directed differentiation
					Microbiology / Virus Screening | 
						|
| Mycoplasma | Negative | 
Genotyping
Karyotyping (Cell Line) | 
					|
| Has the cell line karyotype been analysed? | 
								 Yes 								
																	
												46XY
											 
																				
																																							 | 
						
Other Genotyping (Cell Line) | 
					|

Login to share your feedback, experiences or results with the research community.